KR20220008841A - 인간 면역글로불린 힌지 영역인 두 개의 결합 도메인 사이의 링커 또는 이의 변이체를 포함하는 활성화 가능한 이중특이성 항체 및 이의 용도 - Google Patents

인간 면역글로불린 힌지 영역인 두 개의 결합 도메인 사이의 링커 또는 이의 변이체를 포함하는 활성화 가능한 이중특이성 항체 및 이의 용도 Download PDF

Info

Publication number
KR20220008841A
KR20220008841A KR1020217038644A KR20217038644A KR20220008841A KR 20220008841 A KR20220008841 A KR 20220008841A KR 1020217038644 A KR1020217038644 A KR 1020217038644A KR 20217038644 A KR20217038644 A KR 20217038644A KR 20220008841 A KR20220008841 A KR 20220008841A
Authority
KR
South Korea
Prior art keywords
human
protein
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217038644A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 제임스 조나단 핀레이
Original Assignee
락바디 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 락바디 테라퓨틱스 리미티드 filed Critical 락바디 테라퓨틱스 리미티드
Publication of KR20220008841A publication Critical patent/KR20220008841A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217038644A 2019-05-13 2020-05-13 인간 면역글로불린 힌지 영역인 두 개의 결합 도메인 사이의 링커 또는 이의 변이체를 포함하는 활성화 가능한 이중특이성 항체 및 이의 용도 Pending KR20220008841A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB1906685.1A GB201906685D0 (en) 2019-05-13 2019-05-13 Activatable protein constructs and uses thereof
GB1906685.1 2019-05-13
GBGB1910254.0A GB201910254D0 (en) 2019-05-13 2019-07-17 Activatable protein constructs and uses thereof
GB1910254.0 2019-07-17
GBGB1917678.3A GB201917678D0 (en) 2019-05-13 2019-12-04 Activatable protein constructs and uses thereof
GB1917678.3 2019-12-04
GBGB2001196.1A GB202001196D0 (en) 2019-05-13 2020-01-28 Activatable protein constructs and uses thereof
GB2001196.1 2020-01-28
PCT/EP2020/063362 WO2020229553A1 (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof

Publications (1)

Publication Number Publication Date
KR20220008841A true KR20220008841A (ko) 2022-01-21

Family

ID=67384589

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217038644A Pending KR20220008841A (ko) 2019-05-13 2020-05-13 인간 면역글로불린 힌지 영역인 두 개의 결합 도메인 사이의 링커 또는 이의 변이체를 포함하는 활성화 가능한 이중특이성 항체 및 이의 용도

Country Status (13)

Country Link
US (1) US20230192899A1 (https=)
EP (1) EP3969116A1 (https=)
JP (2) JP7617027B2 (https=)
KR (1) KR20220008841A (https=)
CN (2) CN113840634B (https=)
AU (1) AU2020276891A1 (https=)
BR (1) BR112021022661A2 (https=)
CA (1) CA3138827A1 (https=)
GB (4) GB201906685D0 (https=)
IL (1) IL287890A (https=)
MX (1) MX2021013844A (https=)
SG (1) SG11202112114YA (https=)
WO (1) WO2020229553A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024241208A1 (ko) * 2023-05-19 2024-11-28 서울대학교산학협력단 Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포
WO2025058453A1 (en) * 2023-09-14 2025-03-20 Abl Bio Inc. Methods of treating cancer by administering anti-pd-l1/anti-4-1bb bispecific antibodies

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
EP4034171A1 (en) * 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
JP2023547499A (ja) * 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023144423A1 (en) * 2022-01-31 2023-08-03 LockBody Therapeutics Ltd Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
CA3246893A1 (en) * 2022-03-30 2023-10-05 Centessa Pharmaceuticals (Uk) Limited Activable Bispecific Anti-CD3 and Anti-PD-L1 Proteins and Their Uses
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
CA3251998A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies
GB202302074D0 (en) * 2023-02-14 2023-03-29 Creasallis Ltd Agents, methods and uses thereof
WO2024218512A1 (en) * 2023-04-19 2024-10-24 Centessa Pharmaceuticals (Uk) Limited Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
WO2024218509A1 (en) * 2023-04-19 2024-10-24 Centessa Pharmaceuticals (Uk) Limited Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
WO2026038050A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038047A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038048A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2352763T5 (pl) * 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
AU2015323313B2 (en) * 2014-09-25 2021-04-01 Amgen Inc. Protease-activatable bispecific proteins
KR102499191B1 (ko) * 2016-03-18 2023-02-13 프레드 허친슨 캔서 센터 Cd20 면역요법을 위한 조성물 및 방법
CR20180453A (es) * 2016-03-22 2018-12-05 Hoffmann La Roche Moleculas biespecíficas de células t activadas por proteasas
AU2018250641B2 (en) * 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
EP3668897B1 (en) 2017-08-18 2024-06-05 Centessa Pharmaceuticals (UK) Limited Binding agents
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024241208A1 (ko) * 2023-05-19 2024-11-28 서울대학교산학협력단 Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포
WO2025058453A1 (en) * 2023-09-14 2025-03-20 Abl Bio Inc. Methods of treating cancer by administering anti-pd-l1/anti-4-1bb bispecific antibodies

Also Published As

Publication number Publication date
GB201906685D0 (en) 2019-06-26
SG11202112114YA (en) 2021-11-29
CN113840634B (zh) 2025-07-08
EP3969116A1 (en) 2022-03-23
JP2025039660A (ja) 2025-03-21
GB201910254D0 (en) 2019-08-28
GB202001196D0 (en) 2020-03-11
JP2022532534A (ja) 2022-07-15
BR112021022661A2 (pt) 2022-03-29
CN113840634A (zh) 2021-12-24
GB201917678D0 (en) 2020-01-15
MX2021013844A (es) 2022-03-17
AU2020276891A1 (en) 2021-12-23
JP7617027B2 (ja) 2025-01-17
CN120554533A (zh) 2025-08-29
WO2020229553A1 (en) 2020-11-19
CA3138827A1 (en) 2020-11-19
IL287890A (en) 2022-01-01
US20230192899A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
CN113840634B (zh) 可活化蛋白质构建体及其用途
Paul et al. Cancer therapy with antibodies
US20240327527A1 (en) Activatable antibodies and methods of use thereof
CA2920117C (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
HK1217958A1 (zh) 四价双特异性抗体
CA3092174A1 (en) Pd1 binding agents
CA3181591A1 (en) Antibodies specific to abcb5 and uses thereof
WO2022271987A1 (en) Anti-cd38 antibodies and epitopes of same
CN115279412A (zh) 偶联脂肪酸分子的抗体及其用途
US20240124574A1 (en) Bispecific Antibodies with Charge Pairs and Uses Thereof
CN106164094A (zh) 双特异性抗原结合多肽
CN111788229A (zh) Csf1r结合剂
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
KR20230142738A (ko) 항-oxMIF 방사성면역접합체
US20250002585A1 (en) Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
WO2023273958A1 (zh) 三特异性抗体、其制备方法和用途
KR20240114766A (ko) 인간 메소텔린 결합제
CN120530135A (zh) 抗b7h3抗体和使用方法
HK40082596A (en) Antibodies conjugated with fatty acid molecules and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000